Form 4: Twist Bioscience COO Sells $931K in Stock

Patrick John Finn, President and COO of Twist Bioscience Corp., executed a pre-arranged plan to exercise stock options and sell 23,279 shares of common stock.

Summary

• Patrick John Finn, President and COO of Twist Bioscience Corp. (TWST), reported transactions on January 13, 2026.
• Finn exercised options to acquire 3,279 shares of common stock at an exercise price of $8.82 per share.
• Concurrently, Finn sold 23,279 shares of common stock at a price of $40.00 per share.
• These transactions were conducted under a Rule 10b5-1 trading plan previously adopted on May 13, 2025.
• Following these transactions, Finn directly beneficially owns 312,883 shares of common stock.

Sentiment

Score: 4

Explanation: The transaction represents a significant profit for the insider, which is positive for the individual. However, the net selling of shares, even under a 10b5-1 plan, can be viewed with slight caution by the market, though it's a routine event for executives managing their compensation and diversification.

Positives

• The exercise of options at $8.82 and subsequent sale at $40.00 indicates a significant profit for the reporting person.
• Transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which suggests the sale was not based on new, non-public information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived negatively by the market, potentially signaling a desire for diversification or a lack of confidence.
• The number of shares sold (23,279) is substantial relative to the number of shares acquired (3,279) through option exercise.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May interpret the insider selling as a signal, though the 10b5-1 plan mitigates concerns about opportunistic selling. The significant profit realized by the COO could be seen as a positive indicator of past performance.

Key Dates

Recommendation

While the insider sold a substantial number of shares, the transaction was pre-scheduled under a 10b5-1 plan, which reduces the implication of opportunistic selling based on new, non-public information. This Form 4 primarily reflects personal financial management rather than a direct signal about the company's immediate future performance. Investors should consider this in the broader context of the company's financial reports and market conditions.

Keywords

Twist Bioscience, TWST, Insider Transaction, Form 4, Stock Sale, Option Exercise, Patrick John Finn, 10b5-1 Plan, Biotechnology